Monoclonal antibody to ganglioside gq discriminates between haemopoietic cells and infiltrating neuroblastoma tumour cells in bone marrow
Monoclonal antibody to ganglioside gq discriminates between haemopoietic cells and infiltrating neuroblastoma tumour cells in bone marrow
复制标题
神经节苷脂 gq 单克隆抗体可区分骨髓中的造血细胞和浸润性神经母细胞瘤细胞
DOI：
10.1002/ijc.2910270405
复制
发表时间：
1981
影响因子：
6.4
通讯作者：
M. Greaves
中科院分区：
文献类型：
--
作者：
J. Kemshead;J. Kemshead;F. Walsh;J. Pritchard;M. Greaves
人们正在寻求一种免疫学方法来鉴定神经母细胞瘤向骨髓的最小转移扩散。在这里，我们描述了单克隆抗体 A2B5 对人神经母细胞瘤细胞系和新鲜肿瘤组织的反应性。该试剂针对小鸡视网膜细胞产生，可与所有检测的人类神经母细胞瘤系发生反应，尽管培养物之间的抗原表达存在数量差异。对严重浸润的骨髓抽吸物中肿瘤细胞的分析表明，只有 70% 的样品与 A2B5 发生反应，这表明细胞系上抗原表达的异质性与新鲜肿瘤材料中的相似。尽管检测到对偶尔的白血病骨髓抽吸物有反应性，但 A2B5 对一组人类白血病细胞系或正常人骨髓均没有反应性。我们建议 A2B5 可以成为检测所有神经母细胞瘤细胞向骨髓转移扩散所必需的一组单克隆试剂的一部分。此类试剂可能在自体骨髓移植计划中具有治疗作用，用于在将造血细胞回输给接受高剂量化疗的患者之前去除肿瘤细胞。
An immunological approach has been sought for the identification of minimal metastatic spread of neuroblastoma to bone marrow. Here we describe the reactivity of the monoclonal antibody A2B5 to human neuroblastoma cell lines and fresh tumour tissue. This reagent, raised against chick retinal cells, reacts with all human neuroblastoma lines assayed although quantitative differences in antigenic expression exist between cultures. Analysis of tumour cells in heavily infiltrated bone marrow aspirates indicated that only 70% of the samples reacted with A2B5, suggesting that the heterogeneity seen in the expression of antigen on cell lines is paralleled in fresh tumour material. A2B5 showed no reactivity to either a panel of human leukaemic cell lines or normal human bone marrow, although reactivity to an occasional leukaemic marrow aspirate was detected. We suggest that A2B5 could form part of a panel of monoclonal reagents necessary for detecting metastatic spread of all neuroblastoma cells to bone marrow. Such a group of reagents may be useful therapeutically in a programme of autologous bone marrow transplantation for the removal of tumour cells prior to reinfusion of haemopoietic cells to patients receiving high‐dose chemotherapy.